Stock Research: Medpaces

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Medpaces

NSQ:MEDP US58506Q1094
54
  • Value
    5
  • Growth
    72
  • Safety
    Safety
    9
  • Combined
    29
  • Sentiment
    49
  • 360° View
    360° View
    54
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Medpace Holdings, Inc. is a global clinical contract research organization (CRO) providing full-service clinical development services. The company operates in the biotechnology, pharmaceutical, and medical device industries, offering phase I-IV clinical development services, bio-analytical laboratory services, clinical human pharmacology, imaging, and electrocardiography reading support. Their operations are principally based in North America, Europe, and Asia. In the last fiscal year, the company had a market cap of $8988 million, profits of $656 million, revenue of $2109 million, and 5900 employees.

more

ANALYSIS: With an Obermatt 360° View of 54 (better than 54% compared with alternatives), overall professional sentiment and financial characteristics for the stock Medpaces are above average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Medpaces. The consolidated Growth Rank has a good rank of 72, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. It ranks higher than 72% of competitors in the same industry. The other indicators are below average, namely the Value, Safety, and Sentiment Ranks.The Value Rank at 5 means that the share price of Medpaces is on the high side compared with its peers regarding revenues, profits, and invested capital. The stock price is higher than for 95% of alternative stocks in the same industry. The consolidated Safety Rank has a riskier rank of 9, which means that the company has a riskier financing structure than 91% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. The consolidated Sentiment Rank also has a low rank of 49, indicating professional investors are more pessimistic about the stock than for 51% of alternative investment opportunities. ...read more

more
Index
NASDAQ
D.J. US Health Care
S&P MIDCAP
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 19-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
5 9 8 35
Growth
72 73 97 91
Safety
Safety
9 9 69 77
Sentiment
49 33 100 75
360° View
360° View
54 54 90 79
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
3 34 83 16
Opinions Change
78 22 50 50
Pro Holdings
n/a 56 92 92
Market Pulse
11 46 91 78
Sentiment
49 33 100 75
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
5 9 8 35
Growth
72 73 97 91
Safety Safety
9 9 69 77
Combined
29 29 65 74
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
61 32 38 67
Price vs. Earnings (P/E)
5 42 30 37
Price vs. Book (P/B)
19 17 3 33
Dividend Yield
1 1 1 1
Value
5 9 8 35
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
65 67 82 75
Profit Growth
91 33 73 51
Capital Growth
49 78 89 75
Stock Returns
40 59 87 75
Growth
72 73 97 91
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
31 100 62 100
Refinancing
13 8 3 13
Liquidity
1 1 100 90
Safety Safety
9 9 69 77

Similar Stocks

Discover high‑ranked alternatives to Medpaces and broaden your portfolio horizons.

Aramark

NYQ:ARMK
Country: USA
Industry: Restaurants
Size: X-Large
Full Stock Analysis

Innoviva

NSQ:INVA
Country: USA
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

SSR Mining

NSQ:SSRM
Country: USA
Industry: Gold Production
Size: Large
Full Stock Analysis

Regeneron Pharmaceuticals

NSQ:REGN
Country: USA
Industry: Biotechnology
Size: Large
Full Stock Analysis

Frequently Asked
Questions

The only positive is high growth. The stock is expensive (low Value Rank), risky to finance, and carries critical professional sentiment. This is a risky proposition. Avoid unless you have exceptional conviction that the growth alone will overcome the price and financial risks.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: